Dr. Ankur A. Doshi, M.D.
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Medical school
- University of Texas Medical Branch at Galveston (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 189
Licensed in Texas since 1998, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: University of Texas Medical Branch at Galveston
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
TX license K4677 (first issued 1998; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Memorial Hermann - Texas Medical Center Houston, TX
- Memorial Hermann Memorial City Hospital Houston, TX
- Memorial Hermann Katy Hospital Katy, TX
Medical groups
- Legacy Healthcare Services Inc (3,223 clinicians)
- Kelsey-Seybold Medical Group, PLLC (957 clinicians)
- Wellmed Medical Group PA (646 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 189
- Services billed
- 370
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 245 | 178 |
| Established patient office or other outpatient visit, 30-39 minutes | 33 | 32 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 29 | 29 |
| Administration of influenza virus vaccine | 28 | 28 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 14 | 13 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $29.59 in total to this clinician.
| Astellas Pharma US Inc | $15.47 |
|---|---|
| Amneal Pharmaceuticals LLC | $14.12 |
| Food and Beverage | $29.59 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 9 companies. The companies reported $311,328 in research payments for these studies, mostly to the institutions running them.
- A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company · Completed · NCT05936151 - Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
Alnylam Pharmaceuticals Inc. - Study name not reported
Novo Nordisk As - A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Janssen Research & Development, LLC - A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy…
Janssen Research & Development, LLC - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fi…
Janssen Research & Development, LLC - A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With …
Janssen Research & Development, LLC - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc. - A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Eli Lilly and Company · Completed · NCT05803421
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.